Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Lucanthone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.98 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.98 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.98 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.98 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.98 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.98 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.98 |
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.98 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.98 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.98 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.98 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 2/20 | 0.98 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.98 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.98 |
| ▸ | TOP2A known ✓ | P11388 | 6/20 | 0.74 |
| ▸ | TOP2B known ✓ | Q02880 | 6/20 | 0.74 |
| ▸ | BCHE known ✓ | P06276 | 2/20 | 0.54 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.54 |
| ▸ | APP | P05067 | 7/20 | 0.98 |
| ▸ | MAPT | P10636 | 6/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lucanthone SCHEMBL28172520 | 1.00 | APP (0.98) | APPMAPTCHRM2HTR1AADRA2A | |
| Lucanthone SCHEMBL8004521 | 1.00 | APP (0.98) | APPMAPTCHRM2HTR1AADRA2A | |
| Lucanthone SCHEMBL419165 | 1.00 | APP (0.98) | APPMAPTCHRM2HTR1AADRA2A | |
| Lucanthone SCHEMBL30572937 | 0.99 | APP (1.00) | APPMAPTCHRM2HTR1AADRA2A | |
| Lucanthone SCHEMBL29422254 | 0.99 | APP (1.00) | APPMAPTCHRM2HTR1AADRA2A | |
| Lucanthone SCHEMBL9156 | 0.99 | APP (1.00) | APPMAPTCHRM2HTR1AADRA2A | |
| Lucanthone SCHEMBL1650327 | 0.97 | APP (0.96) | APPMAPTCHRM2HTR1AADRA2A | |
| Lucanthone SCHEMBL7517404 | 0.94 | APP (0.90) | APPMAPTCHRM2HTR1AADRA2A | |
| SCHEMBL13856933 | 0.92 | APP (0.86) | APPMAPTCHRM2HTR1AADRA2A | |
| Becanthone SCHEMBL637068 | 0.91 | APP (0.81) | APPMAPTCHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637467-B2 | Inhibitor of BTK and mutants thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250045728-A1 | INHIBITORS OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. | 2025-02-06 | — | — | US | disclosed |
| US-12086788-B2 | Substituted pyrazines as inhibitors of BTK, and mutants thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2024-09-10 | — | — | US | disclosed |
| CN-117209502-A | Inhibitors of BTK and mutants thereof | 广州麓鹏制药有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-20230140433-A1 | INHIBITORS OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. | 2023-05-04 | — | — | US | disclosed |
| US-20220363689-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. | 2022-11-17 | — | — | US | disclosed |
| US-11501284-B2 | Substituted pyrazines as inhibitors of BTK, and mutants thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2022-11-15 | — | — | US | disclosed |
| US-20220135569-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11501284-B2 | Substituted pyrazines as inhibitors of BTK, and mutants thereof | BTK, SYK, LYN | CHRM2 1912/4885HTR1A 2748/4885ADRA2A 4159/4885 |
| US-20220363689-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | BTK, SYK, LYN | CHRM2 1902/4885HTR1A 4364/4885ADRA2A 4528/4885 |
| US-20220135569-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | BTK, SYK, LYN | CHRM2 1997/4885HTR1A 3936/4885ADRA2A 4516/4885 |
| US-20250045728-A1 | INHIBITORS OF BTK AND MUTANTS THEREOF | BTK, SYK, LYN | CHRM2 1973/4885HTR1A 3410/4885ADRA2A 4498/4885 |
| US-20230140433-A1 | INHIBITORS OF BTK AND MUTANTS THEREOF | BTK, SYK, LYN | CHRM2 1973/4885HTR1A 3410/4885ADRA2A 4498/4885 |
| US-12637467-B2 | Inhibitor of BTK and mutants thereof | BTK, CNKSR1, SYK | CHRM2 3411/4885HTR1A 3969/4885ADRA2A 2431/4885 |
| US-12086788-B2 | Substituted pyrazines as inhibitors of BTK, and mutants thereof | BTK, SYK, LYN | CHRM2 1912/4885HTR1A 2748/4885ADRA2A 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.